Sex differences in the effects of MDMA (ecstasy) on plasma copeptin in healthy subjects

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 9, 2011, Pages 2844-2850

  Simmler, Linda D ^a   Hysek, Cédric M ^a   Liechti, Matthias E ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ARGIPRESSIN; COPEPTIN; DULOXETINE; LACTOSE; NEUROHYPOPHYSIS HORMONE; NORADRENALIN; PLACEBO; SEROTONIN; SODIUM; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; FLUID INTAKE; HUMAN; HUMAN EXPERIMENT; HYPONATREMIA; MALE; NORADRENALIN RELEASE; NORMAL HUMAN; PLASMA OSMOLALITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; RANDOMIZED CONTROLLED TRIAL; SEROTONIN RELEASE; SEX DIFFERENCE; SINGLE DRUG DOSE; SODIUM URINE LEVEL; URINE OSMOLALITY; WATER RETENTION;

ADULT; ARGININE VASOPRESSIN; CROSS-OVER STUDIES; FEMALE; GLYCOPEPTIDES; HUMANS; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; OSMOLAR CONCENTRATION; SEROTONIN AGENTS; SEROTONIN UPTAKE INHIBITORS; SEX CHARACTERISTICS; THIOPHENES;

EID: 80052539622     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-1143     Document Type: Article

References (34)

1. Holden R., Jackson M.A. 1996 Near-fatal hyponatraemic coma due to vasopressin over-secretion after "ecstasy" (3,4-MDMA). Lancet 347:1052 (Pubitemid 26112200)
2. Hartung T.K., Schofield E., Short A.I., Parr M.J., Henry J.A. 2002 Hyponatraemic states following 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') ingestion. QJM 95:431-437 (Pubitemid 34814661)
3. Rosenson J., Smollin C., Sporer K.A., Blanc P., Olson K.R. 2007 Patterns of ecstasy-associated hyponatremia in California. Ann Emerg Med 49:164-171, 171.e1
4. Budisavljevic M.N., Stewart L., Sahn S.A., Ploth D.W. 2003 Hyponatremia associated with 3,4-methylenedioxymethylamphetamine ("ecstasy") abuse. Am J Med Sci 326:89-93 (Pubitemid 36993114)
5. Henry J.A., Fallon J.K., Kicman A.T., Hutt A.J., Cowan D.A., Forsling M. 1998 Low-dose MDMA ("ecstasy") induces vasopressin secretion. Lancet 351:1784 (Pubitemid 28269192)
6. Forsling M., Fallon J.K., Kicman A.T., Hutt A.J., Cowan D.A., Henry J.A. 2001 Arginine vasopressin release in response to the administration of 3,4-methylenedioxymethamphetamine ("ecstasy"): Is metabolism a contributory factor? J Pharm Pharmacol 53:1357-1363 (Pubitemid 32982252)
7. Verrico C.D., Miller G.M., Madras B.K. 2007 MDMA (ecstasy) and human dopamine, norepinephrine, and serotonin transporters: Implications for MDMA-induced neurotoxicity and treatment. Psychopharmacology (Berl) 189:489-503 (Pubitemid 44791219)
8. Iovino M., Steardo L. 1985 Effect of substances influencing brain serotonergic transmission on plasma vasopressin levels in the rat. Eur J Pharmacol 113:99-103 (Pubitemid 15246184)
9. Day T.A. 1989 Control of neurosecretory vasopressin cells by noradrenergic projections of the caudal ventrolateral medulla. Prog Brain Res 81:303-317 (Pubitemid 20062360)
10. Liechti M.E., Vollenweider F.X. 2000 The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine ('ecstasy') in healthy volunteers. J Psychopharmacol 14:269-274
11. Hysek C.M., Simmler L.D., Ineichen M., Grouzmann E., Hoener M.C., Brenneisen R., Huwyler J., Liechti M.E. 15 June 2011 The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA ("ecstasy") in humans. Clin Pharmacol Ther 10.1038/clpt.2011.78
12. Morgenthaler N.G., Struck J., Alonso C., Bergmann A. 2006 Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 52:112-119 (Pubitemid 43032474)
13. Szinnai G., Morgenthaler N.G., Berneis K., Struck J., Müller B., Keller U., Christ-Crain M. 2007 Changes in plasma copeptin, the c-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects. J Clin Endocrinol Metab 92:3973-3978 (Pubitemid 47607649)
14. Balanescu S., Kopp P., Gaskill M.B., Morgenthaler N.G., Schindler C., Rutishauser J. 2011 Correlation of plasma copeptin and vasopressin concentrations in hypo-, iso-, and hyperosmolar states. J Clin Endocrinol Metab 96:1046-1052
15. White T.L., Justice A.J., De Wit H. 2002 Differential subjective effects of D-amphetamine by gender, hormone levels and menstrual cycle phase. Pharmacol Biochem Behav 73:729-741 (Pubitemid 35251831)
16. Stachenfeld N.S., Splenser A.E., Calzone W.L., Taylor M.P., Keefe D.L. 2001 Sex differences in osmotic regulation of AVP and renal sodium handling. J Appl Physiol 91:1893-1901
17. Williams H., Dratcu L., Taylor R., Roberts M., Oyefeso A. 1998 "Saturday night fever": Ecstasy related problems in a London accident and emergency department. J Accid Emerg Med 15:322-326
18. Liechti M.E., Gamma A., Vollenweider F.X. 2001 Gender differences in the subjective effects ofMDMA.Psychopharmacology (Berl) 154: 161-168 (Pubitemid 32186501)
19. Verheyden S.L., Hadfield J., Calin T., Curran H.V. 2002 Sub-acute effects of MDMA (+/-3,4-methylenedioxymethamphetamine, "ecstasy") on mood: Evidence of gender differences. Psychopharmacology (Berl) 161:23-31 (Pubitemid 34437965)
20. Reneman L., Booij J., De Bruin K., Reitsma J.B., De Wolff F.A., Gunning W.B., Den Heeten G.J., Van den Brink W. 2001 Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons. Lancet 358:1864-1869 (Pubitemid 34008653)
21. Arieff A.I. 2006 Influence of hypoxia and sex on hyponatremic encephalopathy. Am J Med 119:S59-S64
22. Ellison D.H., Berl T. 2007 Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med 356:2064-2072 (Pubitemid 46789896)
23. Ayus J.C., Wheeler J.M., Arieff A.I. 1992 Postoperative hyponatremic encephalopathy in menstruant women. Ann Intern Med 117:891-897
24. Cherney D.Z., Davids M.R., Halperin M.L. 2002 Acute hyponatraemia and 'ecstasy': Insights from a quantitative and integrative analysis. QJM 95:475-483 (Pubitemid 34814667)
25. Forsling M.L., Ingram D.L., Stanier M.W. 1976 Effects of various ambient temperatures and of heating and cooling the hypothalamus and cervical spinal cord on antidiuretic hormone secretion and urinary osmolality in pigs. J Physiol 257:673-686
26. Landgraf R., Häcker R., Buhl H. 1982 Plasma vasopressin and oxytocin in response to exercise and during a day-night cycle in man. Endokrinologie 79:281-291 (Pubitemid 12008648)
27. Benzing J., Wellmann S., Achini F., Letzner J., Burkhardt T., Beinder E., Morgenthaler N.G., Haagen U., Bucher H.U., Bührer C., Lapaire O., Szinnai G. 2011 Plasma copeptin in preterm infants: A highly sensitive marker of fetal and neonatal stress. J Clin Endocrinol Metab 96:E982-E985
28. Katan M., Christ-Crain M. 2010 The stress hormone copeptin: A new prognostic biomarker in acute illness. Swiss Med Wkly 140:w13101
29. Grob C.S., Poland R.E., Chang L., Ernst T. 1996 Psychobiologic effects of 3,4-methylenedioxymethamphetamine in humans: Methodological considerations and preliminary observations. Behav Brain Res 73:103-107 (Pubitemid 26008769)
30. Mas M., Farré M., De la Torre R., Roset P.N., Ortuño J., Segura J., Camí J. 1999 Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther 290:136-145 (Pubitemid 29302313)
31. Bruggisser M., Ceschi A., Bodmer M., Wilks M.F., Kupferschmidt H., Liechti M.E. 2010 Retrospective analysis of stimulant abuse cases reported to the Swiss Toxicological Information Centre during 1997-2009. Swiss Med Wkly 140:w13115
32. Cregg M.T., Tracey J.A. 1993 Ecstasy abuse in Ireland. Ir Med J 86: 118-120
33. Liechti M.E., Kunz I., Kupferschmidt H. 2005 Acute medical problems due to ecstasy use. Case-series of emergency department visits. Swiss Med Wkly 135:652-657
34. Sanjurjo E., Nogue S., Miro O., Munne P. 2004 [Analysis of patients attended in an emergency department due to ecstasy consumption]. Med Clin (Barc) 123:90-92 (Spanish)